MARCH 10, 2020

Trial Implicates MAP as Treatable Cause of Crohn’s Disease

Treatment with an oral antibiotic targeting Mycobacterium avium paratuberculosis (MAP) led to significant improvement in patients with Crohn’s disease, including clinical remissions, according to the results of a multinational randomized trial.

The drug, a fixed-dose combination of clarithromycin, rifabutin and clofazimine (RHB-104, RedHill Biopharma) is yet to be approved for Crohn’s. However, the findings strengthen the case that MAP infection may be the cause of at least some